Why Japan Is the Hardest Asian Market for Medical Devices (And Still Worth It)

Japan's medical device market is the third largest in the world — roughly USD 17–20 billion annually. Every significant medical device company wants to be there. And yet Japan consistently tops the list of markets that take longer, cost more, and require more organizational patience than anticipated. Both things are true simultaneously, which is what makes Japan so interesting to analyze.

This guide covers what actually makes Japan difficult, how PMDA's regulatory system works, and how to use registration data to make better decisions before you commit the time and resources that Japan market entry requires.

The two pathways: shonin and ninsho

Japan has two distinct regulatory pathways for medical devices, and understanding the difference is the first thing anyone working on a Japan strategy needs to get right.

Shonin (承認) means ministerial approval. It's required for high-risk devices — Class III and Class IV — and is granted by the Ministry of Health, Labour and Welfare (MHLW) following a technical review conducted by PMDA. Shonin is the more demanding pathway: expect full technical documentation, clinical data review, and in many cases, data from clinical studies conducted in Japan. Realistic timeline for a Class IV shonin is 2–4 years from submission of a complete dossier, assuming no major deficiencies. Class III shonin timelines are somewhat shorter but still typically 18 months to 3 years.

Ninsho (認証) means third-party certification. It applies to designated Class II devices and some Class III devices that fall within established Japanese technical standards — the "designated controlled medical device" category. Certification is handled by PMDA-registered conformity assessment bodies, not MHLW directly. This makes ninsho meaningfully faster: a complete, clean submission for a straightforward Class II device can go through ninsho in 6–12 months. For devices where ninsho is available, it's the preferred path.

The practical question is: does your device qualify for ninsho? The answer depends on whether a Japanese technical standard (JIS or Japanese Industrial Standard equivalent) exists for your device type, and whether your device falls within the scope of "designated controlled medical devices." This determination requires Japan-specific regulatory expertise — it's not always obvious from the device classification alone.

The Marketing Authorization Holder requirement

This is Japan's most structurally distinctive feature. Unlike every other Asian market, where a foreign manufacturer can hold registrations through a local agent or subsidiary acting on their behalf, Japan requires that approvals and certifications be held by a Marketing Authorization Holder (MAH) — a Japanese legal entity that takes full regulatory, quality system, and post-market surveillance responsibility for the device.

What this means in practice:

• The MAH's name appears on the approval, not the foreign manufacturer's name
• The MAH must have a quality management system that covers the device
• Post-market surveillance obligations (adverse event reporting, periodic safety reports) are the MAH's responsibility in Japan
• If the MAH relationship ends, the approval stays with the MAH — changing MAH requires a significant regulatory process

Foreign manufacturers typically establish a Japanese subsidiary (WFOE-equivalent) to serve as MAH, or they partner with a Japanese company that acts as MAH on their behalf. Large Japanese trading companies (shosha) historically played this role for many foreign device manufacturers entering Japan. The partnership model involves a loss of control that the subsidiary model doesn't — but establishing a Japanese subsidiary has its own costs and management overhead.

When you search PMDA registration data, the MAH is the entity listed as the approval holder. Identifying the underlying OEM — particularly for devices managed by a trading company rather than a manufacturer's subsidiary — requires inference. This is one of the areas where Meridian Trace's OEM inference layer is particularly useful for Japan research.

Japanese clinical data: what's actually required

Japan's requirement for Japan-specific clinical data has been the single largest barrier for foreign manufacturers historically. The underlying logic was that Japanese patients may have physiological differences relevant to device performance — particularly true for cardiovascular devices, where body size differences affect sizing, and for orthopedic implants.

The situation has evolved. PMDA has progressively opened to accepting foreign clinical data under specific conditions, particularly where: (a) the patient population in the foreign trials is sufficiently comparable to Japanese patients, (b) the device type doesn't have Japanese-specific clinical concerns, and (c) the foreign trial was conducted to GCP standards acceptable to MHLW.

For novel Class IV devices — particularly cardiac and neurological — Japan-specific clinical data is still commonly required or strongly preferred, either as the primary evidence base or as a supplemental bridging study. For Class III ninsho-eligible devices with established track records, foreign data is more readily accepted.

The practical implication for planning: don't assume your FDA PMA clinical data will be accepted as-is for a Japan shonin. The questions Japan asks about clinical evidence are not identical to what FDA asked. Get a Japan-specialized regulatory consultant to review your clinical package before you plan your timeline.

Why Japan is still worth it

Given the effort required, it's worth being explicit about why Japan remains a priority market for most serious medical device companies.

First, the market size. USD 17–20 billion annually, with a patient population that has both high healthcare utilization rates and strong public health insurance coverage. Japan's universal health insurance system means there's a payer for devices that clear reimbursement — and Japan's reimbursement system, while complex, has historically supported premium pricing for innovative technology.

Second, the quality of the market. Japan's hospitals are sophisticated. Japanese clinicians are demanding. A device that succeeds in Japan has demonstrated performance in a rigorous environment, which carries weight in other markets and with investors.

Third, the competitive signal. Companies that are in Japan's PMDA database have committed years and significant resources to get there. Knowing who's registered — and who isn't — tells you something about competitive commitment to the Asia-Pacific region that you can't get from annual reports.

How to read the PMDA public database

PMDA maintains a public database of approved and certified devices, accessible at the PMDA website. The database is searchable but primarily in Japanese, and the data structure requires familiarity with Japanese regulatory terminology to navigate effectively.

Key fields in PMDA data:

• Approval number — identifies shonin approvals, includes year and sequence
• Certification number — identifies ninsho certifications, different format
• MAH name — the Japanese entity holding the approval
• Generic name — the PMDA-assigned device category name (in Japanese)
• Brand/trade name — the commercial name (often in English or katakana)
• Classification — Class I through IV

Meridian Trace normalizes PMDA data into English-language search results, allowing you to search by manufacturer name (including MAH), device type, and registration number without navigating Japanese-language government systems.

Using registration data for Japan strategy

Before committing to Japan entry, registration data can answer several important questions:

Who's already there in your device category? Searching PMDA for your device type shows who has already invested in Japan entry. If five major competitors have PMDA approvals in your category and the sixth doesn't, that tells you something about the relative attractiveness of Japan for that product type.

Who is your likely competition? The Japanese market often has domestic competitors — Japanese medical device companies — that don't compete in your home market but are strong in Japan. Knowing who they are and what they're registered for helps you understand the competitive environment you're entering.

What MAH structures are common in your category? Looking at who is listed as MAH for foreign devices in your category tells you something about the MAH options available. If most competitors use their own Japanese subsidiaries rather than trading company partnerships, that's a signal about what's worked for others in your space.

How many registrations does your target partner have? If you're evaluating a Japanese company as a potential MAH partner or distributor, checking their PMDA registration portfolio tells you about their regulatory competence and their current device commitments.

The bottom line on Japan

Japan takes longer than any other Asian market. The investment in regulatory strategy, clinical evidence, and MAH infrastructure is substantial. But Japan's market size, sophistication, and commercial value justify the effort for most high-risk and innovative device categories. The companies that succeed in Japan almost universally say they wish they'd started earlier — not that they wish they'd skipped it.

The best time to start Japan research is before you've committed to a specific timeline. Understanding who's already in the market, what the approval landscape looks like for your device category, and what the realistic timelines are should inform your strategic planning, not your crisis management.